source
- Amgen ends partnership with TScan Therapeutics as Amylyx announces $350 million offeringAmgen announced it is terminating its collaboration with TScan Therapeutics, a Waltham, Massachusetts company focused on T‑cell therapies. The decision ends a partnership that had been aimed at de…
- Moderna and Merck cancer vaccine returns ‘landmark’ result in melanomaAt an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna shares.BioPharma Dive · 1d ago↗ source